Brief: Merus’ Petosemtamab With Pembrolizumab Interim Data Demonstrates Robust Efficacy And Durability In 1L Pd-L1+ R/M Hnscc
22/05/2025 22:32
Merus NV 2GH.F: MERUS’ PETOSEMTAMAB WITH PEMBROLIZUMAB INTERIM DATA DEMONSTRATES ROBUST EFFICACY AND DURABILITY IN 1L PD-L1+ R/M HNSCC Source text: ID:nGNXbc5kzQ Further company coverage: 2GH.F
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab